The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic. Summit, NJ, USA 27 Jul 2021 Seqirus offers a...

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool. Liverpool, UK 01 Jun 2021 Seqirus Liverpool is the...

This news release is intended for Health Professional media only. Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) at the...

Maidenhead, UK 14 Dec 2020 Seqirus, a global leader in influenza prevention and influenza pandemic response, today presented new late-breaking data from a systematic review and meta-analysis at...

11 Dec 2020 The University of Queensland (UQ) and CSL today announce that the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine has shown that it elicits a robust response towards the virus and...

16 Nov 2020 Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary...

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited to its World’s Best Employers 2020 list. It...

The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza...

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...

Summit, NJ 30 Jul 2020 Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season Seqirus is...